A3P Biomedical

Stockholm3 independently validated at the world-renowned Martini Klinik

23 August 2024 – Stockholm, Sweden – Stockholm3 has been independently, externally validated at the Martini Klinik, the world-renowned prostate cancer center in Hamburg, Germany. The Martini validation study demonstrated results consistent with previous Stockholm3 studies, achieving a 52 percent reduction of unnecessary biopsies. “The results of our validation study of Stockholm3 further support its...

Stockholm 3 commercially available in the US

A3P Biomedical AB, a leading Swedish diagnostics company specializing in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, are excited to announce that Stockholm3 for early detection of prostate cancer is now commercially available as a Lab Developed Test (LDT) throughout the United States. 3 July 2024, - Prostate cancer is the...
Kungsgatan 24, SE 111 35 Stockholm, Sweden

+46 10 1823300